The influence of the immune system on early human lung growth
Understanding the mechanisms in lung formation could develop new therapeutic approaches for respiratory conditions.
List view / Grid view
A drug target is anything within a living organism to which a drug is directed and/or binds, resulting in a change in its behaviour or function.
Understanding the mechanisms in lung formation could develop new therapeutic approaches for respiratory conditions.
Cancer treatment may be majorly impacted by new findings about the polymerase theta-mediated end joining time DNA repair pathway.
NETs require epidermal growth factor to grow, meaning that inhibiting EGF receptors could treat these types of tumours.
The new small molecule targets the glutamate system, reducing MS-like symptoms and repairing damaged myelin in two different animal models.
Astrocyte plasticity is correlated with upregulation of the Galectin 3 protein, which may greatly contribute to biomarker discovery.
Researchers found heightened SCAN enzyme activity in humans and mice with diabetes results in excessive nitric oxide on insulin receptors.
Discovery about the NPM1c variant could lead to new drugs targeting the cell growth of acute myeloid leukaemia.
By mapping the genome, scientists have discovered how IKAROS enables differentiation of hematopoietic stem cells into B cells.
Findings about how erythrocytes interact with brain capillaries offers new potential treatments for brain microhaemorrhages.
An advanced computational model enables scientists to study how cancer cells navigate through blood vessels.
This November edition of our Women in Stem series spotlights Andrea Pfeifer, CEO and Co-Founder of AC Immune SA. Dr Andrea Pfeifer co-founded AC Immune SA in 2003, since when she has served as a Director on the Board, successfully leading it to an IPO in 2016. Under her leadership,…
A signalling mechanism for ventricular fibrillation involving the stress kinases p38γ and p38δ has been discovered.
Novel findings about the tafazzin gene offers a potential new target and drug candidate for Barth syndrome.
An epigenetic pathway is mediated by a certain protein that could potentially reverse vascular remodelling in pulmonary hypertension.
Dr Catherine Pickering, CEO of iOnctura, the clinical stage biopharmaceutical company delivering pioneering cancer treatments to patients with unmet medical needs, is at the forefront of cancer drug discovery. Dr Pickering and her team identify targets that have crucial roles in multiple tumour survival pathways, collaborate with world-renowned scientists and…